Journal article

The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder A Systematic Review

David Coghill

CNS Drugs | ADIS INT LTD | Published : 2010


Funding Acknowledgements

No sources of funding were used to prepare this review. Dr Coghill's department has had research support from Eli Lilly, Janssen Cilag and Shire. He has served in an advisory or consultancy role for Eli Lilly, Janssen Cilag, Pfizer, Shire, Flynn, Schering-Plough and UCB. He has received conference attendance support or was paid for public speaking by Eli Lilly, Janssen McNeil, UCB, Shire and Flynn.